AU2008335025A1 - Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor - Google Patents

Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor Download PDF

Info

Publication number
AU2008335025A1
AU2008335025A1 AU2008335025A AU2008335025A AU2008335025A1 AU 2008335025 A1 AU2008335025 A1 AU 2008335025A1 AU 2008335025 A AU2008335025 A AU 2008335025A AU 2008335025 A AU2008335025 A AU 2008335025A AU 2008335025 A1 AU2008335025 A1 AU 2008335025A1
Authority
AU
Australia
Prior art keywords
day
sorafenib
group
tumor
dtic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008335025A
Other languages
English (en)
Inventor
Israel Rios
Cynthia W. Tuthill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of AU2008335025A1 publication Critical patent/AU2008335025A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008335025A 2007-12-13 2008-12-12 Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor Abandoned AU2008335025A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1347607P 2007-12-13 2007-12-13
US61/013,476 2007-12-13
PCT/US2008/086545 WO2009076587A1 (en) 2007-12-13 2008-12-12 Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor

Publications (1)

Publication Number Publication Date
AU2008335025A1 true AU2008335025A1 (en) 2009-06-18

Family

ID=40755899

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008335025A Abandoned AU2008335025A1 (en) 2007-12-13 2008-12-12 Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor

Country Status (8)

Country Link
US (1) US20100267637A1 (enExample)
EP (1) EP2240194A4 (enExample)
JP (1) JP2011506473A (enExample)
CN (1) CN101945664A (enExample)
AR (1) AR069769A1 (enExample)
AU (1) AU2008335025A1 (enExample)
CA (1) CA2708229A1 (enExample)
WO (1) WO2009076587A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI683667B (zh) * 2014-10-21 2020-02-01 開曼群島商賽生製藥國際有限公司 用免疫刺激物治療癌症

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2604845A1 (de) * 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US20070292392A1 (en) * 2006-06-15 2007-12-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma

Also Published As

Publication number Publication date
CA2708229A1 (en) 2009-06-18
US20100267637A1 (en) 2010-10-21
CN101945664A (zh) 2011-01-12
WO2009076587A1 (en) 2009-06-18
AR069769A1 (es) 2010-02-17
EP2240194A4 (en) 2011-12-21
JP2011506473A (ja) 2011-03-03
EP2240194A1 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
JP7133070B2 (ja) ベンダムスチンの製剤
ES2943668T3 (es) Composiciones líquidas de bendamustina para su uso en un método para tratar afecciones que responden a la bendamustina en pacientes que requieren volúmenes reducidos para administración
HU220599B1 (hu) Eljárás komplementer inhibitorokat tartalmazó, nekrotizáló véredénylézió kezelésére alkalmas gyógyászati készítmények előállítására
Liang et al. Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy
US20100317583A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
US11993640B2 (en) Treating inflammatory lung disease
US20100330093A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
Wilson et al. Antibiotic prophylaxis in cardiac surgery: a prospective comparison of two dosage regimens of teicoplanin with a combination of flucloxacillin and tobramycin
Stewart Pegvisomant: an advance in clinical efficacy in acromegaly
CN115501231A (zh) 预防和/或治疗肝癌的联用药物组合物及其应用
AU2008335025A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor
Glick et al. Phase I clinical trials of WR-2721 with alkylating agent chemotherapy
KR20210039414A (ko) 암의 치료를 위한 병용 요법
KR20210039413A (ko) 암의 치료를 위한 병용 요법
KR20150060660A (ko) 이산화탄소를 용해시킨 액체 의약 및 이를 이용하는 치료 방법
Boehme et al. Amifostine‐induced fever: case report and review of the literature
US20130079416A1 (en) Homeopathic medicament comprising phenacetin for the treatment of cancer
HK40097690A (en) Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
HK40013204A (en) Bendamustine liquid compositions for use in method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
CN111494600A (zh) 一种药物组合物及治疗免疫力低下疾病的药物
Young et al. Naloxone‐Responsive Hypotension in a Patient with an ACTH‐Secreting Tumor
Celik et al. Medical therapy of acromegaly in Turkey

Legal Events

Date Code Title Description
MK3 Application lapsed section 142(2)(c) - examination deferred under section 46 no request for examination